7/102 sources · 2 publishersUpdated Oct 9, 12:05 UTC
HC Wainwright downgrades Pacira BioSciences to Neutral with $36.50 price target
HC Wainwright lowered its rating on Pacira BioSciences to Neutral and set a price target of $36.50 per share. The downgrade references Viatris' pending acquisition of Pacira at the same price, citing slower growth and competitive pressures. The stock was trading at $36.39, up 44.40% over the past five days and 45.50% year‑to‑date.
Why it matters
The downgrade may temper investor enthusiasm despite recent strong price gains, while the $36.50 target aligns with the agreed acquisition price, indicating the deal price is viewed as fair by the analyst.
Key facts
- 1HC Wainwright downgraded Pacira BioSciences to Neutral. tradingview.com
- 2HC Wainwright set a price target of $36.50 per share for Pacira BioSciences. tradingview.com
- 3The downgrade references Viatris' acquisition agreement at $36.50 per share. tradingview.com
- 4Pacira BioSciences was trading at $36.39 on Nasdaq. marketscreener.com
- 5The stock rose 44.40% over the prior five days. marketscreener.com
- 6The stock rose 45.50% year‑to‑date. marketscreener.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.